Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection
Chronic hepatitis delta is the most severe form of viral hepatitis and is associated with rapid progression of liver-related diseases and a high risk of hepatocellular carcinoma development. To date, there are only limited treatment options available. Tobevibart and elebsiran are currently being evaluated in clinical trials for the treatment of HDV (phase III) and for the treatment of HBV (phase II). The current study demonstrates that tobevibart and elebsiran are efficacious in preclinical models of HBV/HDV coinfection, supporting their clinical development.
Authors
- Jiayi Zhou (ORCID: https://orcid.org/0000-0002-4231-3422)
- Davide Corti (ORCID: https://orcid.org/0000-0002-5797-1364)
- Florian A. Lempp (ORCID: https://orcid.org/0000-0001-6103-8078)
- Lisa A. Purcell (ORCID: https://orcid.org/0000-0002-9565-2030)
- Andreas S. Puschnik (ORCID: https://orcid.org/0000-0002-9605-9458)
- Hannah Kaiser (ORCID: https://orcid.org/0000-0002-3991-7401)
- Eduardo Melani Rocha (ORCID: https://orcid.org/0000-0001-9888-7313)
- Ashley N Terrell
Institutions
- Vir Biotechnology (Switzerland) (CH)
- VIR Biotechnology (United States) (US)
Publication Details
- Journal
- JHEP Reports
- Published
- 2025-03-23
- DOI
- https://doi.org/10.1016/j.jhepr.2025.101400
- Citations
- 4
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.42
Funders
- Vir Biotechnology